Chlorproguanil−Dapsone−Artesunate versus Artemether−Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria

Zul Premji, Rich E Umeh, Seth Owusu-Agyei, Fabian Esamai, Emmanuel U Ezedinachi, Stephen Oguche, Steffen Borrmann, Akintunde Sowunmi, Stephan Duparc, Paula L Kirby, Allan Pamba, Lynda Kellam, Robert Guiguemdé, Brian Greenwood, Stephen A Ward and Peter A Winstanley

PLOS ONE, 2009, vol. 4, issue 8, 1-11

Abstract: Background: Chlorproguanil−dapsone−artesunate (CDA) was developed as an affordable, simple, fixed-dose artemisinin-based combination therapy for use in Africa. This trial was a randomized parallel-group, double-blind, double-dummy study to compare CDA and artemether−lumefantrine (AL) efficacy in uncomplicated Plasmodium falciparum malaria and further define the CDA safety profile, particularly its hematological safety in glucose-6-phosphate dehydrogenase (G6PD) -deficient patients. Methods and Findings: The trial was conducted at medical centers at 11 sites in five African countries between June 2006 and August 2007. 1372 patients (≥1 to

Date: 2009
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0006682 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 06682&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0006682

DOI: 10.1371/journal.pone.0006682

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().